This article is more than 5 years old. Information may no longer be current.

Cushing’s syndrome investigational drug receives patent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Patent and Trademark office recently granted a patent to Strongbridge Biopharma Plc for the company’s investigational drug COR-003 for the treatment of Cushing’s syndrome.

COR-003 (levoketoconazol) is a cortisol inhibitor that is currently being studied in a phase 3 trial.

“This patent is an important step forward in our research efforts in Cushing’s syndrome and for our lead investigational drug candidate, COR-003,” Matthew Pauls, president and chief executive officer of Strongbridge Pharma, said in the release.

The drug may reduce C-reactive protein (CRP) levels as well as systemic inflammation through a once-daily dose of levoketoconazole.

“Our phase 3 trial is designed to evaluate the overall safety and efficacy of COR-003 in patients with elevated levels of cortisol due to endogenous Cushing’s syndrome,” Pauls said. “We look forward to evaluating the key secondary endpoint data related to the potential benefits of reducing CRP levels and systemic inflammation in this patient population.”